$2.4
Insights on Nanoviricides Inc
In the last 3 years, Novo Nordisk A/s has given 235.1% return, outperforming this stock by 271.1%
7.42%
Downside
Day's Volatility :9.32%
Upside
2.04%
58.33%
Downside
52 Weeks Volatility :59.84%
Upside
3.61%
Period | Nanoviricides Inc | Index (Russel 2000) |
---|---|---|
3 Months | 98.35% | 0.0% |
6 Months | 104.08% | 0.0% |
1 Year | 105.13% | 0.0% |
3 Years | -36.0% | -22.6% |
Market Capitalization | 28.4M |
Book Value | $0.9 |
Earnings Per Share (EPS) | -0.82 |
PEG Ratio | 0.0 |
Wall Street Target Price | 6.5 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -40.78% |
Return On Equity TTM | -65.85% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -9.0M |
Diluted Eps TTM | -0.82 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.67 |
EPS Estimate Next Year | -0.9 |
EPS Estimate Current Quarter | -0.19 |
EPS Estimate Next Quarter | -0.2 |
What analysts predicted
Upside of 170.83%
Sell
Neutral
Buy
Nanoviricides Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Nanoviricides Inc | 71.43% | 104.08% | 105.13% | -36.0% | -52.38% |
Moderna, Inc. | 21.03% | 85.08% | 14.68% | -28.27% | 659.22% |
Regeneron Pharmaceuticals, Inc. | 3.22% | 20.18% | 31.88% | 93.3% | 227.58% |
Novo Nordisk A/s | 8.85% | 34.38% | 71.83% | 235.07% | 463.44% |
Vertex Pharmaceuticals Incorporated | 16.81% | 34.1% | 40.6% | 123.97% | 174.53% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Nanoviricides Inc | NA | NA | 0.0 | -0.67 | -0.66 | -0.41 | NA | 0.9 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.14 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 28.89 | 28.89 | 1.46 | 44.13 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 46.97 | 46.97 | 2.36 | 3.5 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 29.59 | 29.59 | 0.53 | 17.08 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Nanoviricides Inc | Buy | $28.4M | -52.38% | NA | 0.0% |
Moderna, Inc. | Buy | $54.6B | 659.22% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $108.0B | 227.58% | 28.89 | 29.45% |
Novo Nordisk A/s | Buy | $602.6B | 463.44% | 46.97 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $117.5B | 174.53% | 29.59 | 39.46% |
nanoviricides, inc., a nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. its products pipeline includes herpecide dermal topical and eye drops for the treatment of shingles, phn, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and herpecide intraocular injection for viral acute retinal necrosis. the company also develops flucide broad-spectrum anti-influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; nanoviricide eye drops for viral diseases of the external eye; denguecide for treatment of all types of dengue viruses; and hivcide that is an escape-resistant anti-hiv nanoviricide. in addition, it is also involved in research and development of other nanoviricides drug projects for treatment of different viruses and indications; and herpecide program expansion drug projects for different herpes viruses for different indications. nanovir
Organization | Nanoviricides Inc |
Employees | 7 |
CEO | Dr. Anil R. Diwan Ph.D. |
Industry | Health Technology |
A Spac I Acquisition Corp
$2.40
+0.0%
Keyarch Acquisition Corp
$2.40
+0.0%
Connexa Sports Technologies Inc
$2.40
+0.0%
Us Value Etf
$2.40
+0.0%
First Wave Biopharma Inc
$2.40
+0.0%
Global X Msci Next Emerging
$2.40
+0.0%
Fat Projects Acquisition Corp
$2.40
+0.0%
Goal Acquisitions Corp
$2.40
+0.0%
Capital Link Global Fintech
$2.40
+0.0%